Man’s Best Friends Therapeutics

Ambler, United States Founded: 2008 • Age: 18 yrs
Gene-based vaccines for companion animal diseases are developed.

About Man’s Best Friends Therapeutics

Man’s Best Friends Therapeutics is a company based in Ambler (United States) founded in 2008.. Man’s Best Friends Therapeutics has raised $2.7 million across 6 funding rounds from investors including National Science Foundation and Ben Franklin Technology Partners. Man’s Best Friends Therapeutics offers products and services including T-Max™ DNA Vaccine Platform. Man’s Best Friends Therapeutics operates in a competitive market with competitors including Sana Biotechnology, Janux Therapeutics, Carisma Therapeutics, GigaGen and Kronos Bio, among others.

  • Headquarter Ambler, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Mbf Therapeutics, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Veterinary & Animal Health
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $2.7 M (USD)

    in 6 rounds

  • Latest Funding Round
    $256 K (USD), Grant

    Jan 01, 2022

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Man’s Best Friends Therapeutics

Man’s Best Friends Therapeutics offers a comprehensive portfolio of products and services, including T-Max™ DNA Vaccine Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform for creating DNA vaccines against animal infectious diseases.

Funding Insights of Man’s Best Friends Therapeutics

Man’s Best Friends Therapeutics has successfully raised a total of $2.7M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $256 thousand completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round Grant — $256,000
  • First Round

    (15 Mar 2010)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2022 Amount Grant - Man’s Best Friends Therapeutics Valuation

investors

Sep, 2020 Amount Seed - Man’s Best Friends Therapeutics Valuation

investors

May, 2019 Amount Seed - Man’s Best Friends Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Man’s Best Friends Therapeutics

Man’s Best Friends Therapeutics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include National Science Foundation and Ben Franklin Technology Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Technology ecosystem growth is supported in Southeastern Pennsylvania.
Founded Year Domain Location
A government-backed foundation providing seed-stage investments to support small businesses.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Man’s Best Friends Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Mans Best Friends Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Man’S Best Friends Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Man’s Best Friends Therapeutics

Man’s Best Friends Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Janux Therapeutics, Carisma Therapeutics, GigaGen and Kronos Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Immunotherapeutics for cancer treatment are developed to target solid tumors.
domain founded_year HQ Location
Chimeric antigen receptor macrophages are developed for cancer treatment.
domain founded_year HQ Location
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
Developer of immunotherapies for the treatment of cancer and autoimmune diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Man’S Best Friends Therapeutics

Frequently Asked Questions about Man’s Best Friends Therapeutics

When was Man’s Best Friends Therapeutics founded?

Man’s Best Friends Therapeutics was founded in 2008 and raised its 1st funding round 2 years after it was founded.

Where is Man’s Best Friends Therapeutics located?

Man’s Best Friends Therapeutics is headquartered in Ambler, United States. It is registered at Ambler, Pennsylvania, United States.

Is Man’s Best Friends Therapeutics a funded company?

Man’s Best Friends Therapeutics is a funded company, having raised a total of $2.7M across 6 funding rounds to date. The company's 1st funding round was a Seed of $605K, raised on Mar 15, 2010.

What does Man’s Best Friends Therapeutics do?

Founded in 2008, Mans Best Friends Therapeutics operates from Ambler, United States, within the animal health sector. Gene-based checkpoint inhibitors and immune-modulators are developed for treating cancer and infectious diseases in companion animals. Proprietary viral and non-viral delivery systems are employed to enhance vaccine efficacy. Focus is placed on the companion animal market, with ongoing advancements in therapeutic options.

Who are the top competitors of Man’s Best Friends Therapeutics?

Man’s Best Friends Therapeutics's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.

What products or services does Man’s Best Friends Therapeutics offer?

Man’s Best Friends Therapeutics offers T-Max™ DNA Vaccine Platform.

Who are Man’s Best Friends Therapeutics's investors?

Man’s Best Friends Therapeutics has 2 investors. Key investors include National Science Foundation, and Ben Franklin Technology Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available